Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following the annual reconstitution of the Russell stock indexes. According to the announcement, the Russell 2000 Index, which is a subset of the Russell 3000(R) Index, measures the performance of the small-cap segment of the equity market in the United States and includes an estimated 2,000 of the smallest securities based on a combination of their market cap and current index membership. Investment managers and institutional investors commonly rely on the Russell Index for index funds and as benchmarks for active investment strategies; approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. The indexes are part of global index leader FTSE Russell, which provides innovative benchmarking, analytics and data solutions for investors worldwide. “We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index,” said CNS Pharmaceuticals CEO John Climaco in the press release. “As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (‘GBM’), we believe this inclusion well-positions us to drive market awareness. We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”

To view the full press release, visit https://ibn.fm/Lsa9D

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces Expanded East Coast Capacity to Meet Surging Demand

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER),the country’s largest independent alkaline water company, today announced that two of its leading suppliers have expanded their capacity by opening east coast facilities. According to the update, the company’s exclusive arrangements with these manufacturers will alleviate raw material concerns during its east coast expansion. Additionally, to meet anticipated demand, the company intends to add three new strategically located co-packers prior to the end of the third quarter. “As we position ourselves for continued growth, we continue to deploy assets that allow our production to exceed increased demand for Alkaline88(R),” said Ricky Wright, president and CEO of The Alkaline Water Company. “While much of the industry finds itself squeezed with raw material demands and capacity constraints, we’ve never been stronger. Our foresight to find multiple domestic sources for our raw materials paid dividends last year. Over the last six months, two of our west coast providers have opened operating facilities on the east coast.”

To view the full press release, visit https://ibn.fm/hpaHV

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products Inc. includes the company’s lab-tested, hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules, and gummies. To learn more about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in The Alkaline Water Company Inc. WTER | Leave a comment

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Set To Benefit from a Sustained Silver Demand Boom from the Electric Vehicle Sector

  • Battery-powered electric vehicles are set to be a significant demand driver for silver in coming years
  • The expected increase in annual silver demand from the electric vehicle sector over the next four years is estimated to equal 10% of 2021’s global silver production
  • Excellon Resources is currently executing ongoing precious metals projects in Mexico, Idaho and Germany
  • The company recently revealed that its Mexican operations resulted in a 37% YoY increase in silver production as of the fourth quarter of 2020

Fifty grams is slightly more than the weight of an average golf ball, yet it also represents the estimated silver content contained within a battery electric vehicle (“BEV”) (https://ibn.fm/IzGx9). Silver has historically enjoyed widespread usage within the automotive sector, a reflection of its superior electrical conductivity properties, excellent oxide resistance and durability under harsh operating environments. With electric vehicles rapidly rising as a proportion of global automotive sales, the sector is transforming into a powerful demand center for silver, with The Silver Institute forecasting that the automotive industry will absorb nearly 90 million ounces of silver annually by 2025, a significant increase from this year’s anticipated demand of 61 million ounces (1,900t). To put that figure into context, the expected annual demand from the electric vehicle sector is expected to increase over the next four years to over 10 percent of annual global silver production, based on 2021 projections (https://ibn.fm/ZuQCf). The surge in demand should be particularly advantageous for companies such as Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany.

Silver’s unique properties make it difficult to replace across a wide and growing array of automotive applications; furthermore, and unlike platinum group metals, the use of silver is not concentrated within a single automotive component like a catalytic converter. Rather, silver components can be found across a myriad of vehicular applications, including reversing cameras, automotive lenses, and fuel management systems, making the precious metal relatively harder to substitute. A recent study carried out by The Silver Institute has estimated the average internal combustion engine (“ICE”) vehicle to consume 15-28 grams (0.5-0.9 ounces) of silver, a figure which would increase to 18-34 grams for hybrid vehicles and to 25-50 grams for the average BEV. Notably, that figure does not take into account ancillary services which also require the use of silver, such as the construction of charging stations and charging points for electric vehicles.

While silver’s longer-term demand outlook looks bright, driven by surging demand from electric vehicle manufacturers as well as from the solar/photovoltaic industry where silver is a key component utilized in the manufacture of solar cells, sustained growth in silver mine production will necessitate further investment to bring earlier stage projects into production, thereby offsetting losses from reserve depletion and grade decline. 

Excellon Resources is currently working towards developing a precious metals growth pipeline across a myriad of geographies, including: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho boasting strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany. Excellon has seen particularly promising results from its Platosa Mine located in Durango, Mexico. Over the course of 2020, the company revealed that its Mexican-based mining operations had resulted in a 37 percent year-over-year increase in silver production, with lead output rising by 32 percent and zine production growing by 19 percent (https://ibn.fm/kQwN4). 

Excellon has also updated the market in April 2021 of the results of further underground expansion and exploration drilling at the Platosa Mine, which resulted in the discovery of additional high-grade silver deposits. As per the company’s announcement, further definition and expansion of the Guadalupe North, 623, NE-1 and NE-1S mantos, with results from underground drilling including:

  • 1,293 g/t silver equivalent (“AgEq”) over 6.5 metres (618 g/t Ag, 10.1% Pb and 12.0% Zn) in EX21UG565;
  • 1,571 g/t AgEq over 4.6 metres (688 g/t Ag, 14.5% Pb and 14.9% Zn) in EX21UG564; and
  • 1,031 g/t AgEq over 4.6 metres (359 g/t Ag, 4.9% Pb and 15.9% Zn) in EX20UG522A, including 1,531 g/t AgEq over 1.3 metres (573 g/t Ag, 8.6% Pb and 21.5% Zn).

With rising environmental awareness and a growing transition away from fossil fuels set to drive further growth of both the electric vehicle and photovoltaic sectors, silver demand and price momentum are expected to continue their ongoing rise in the coming future. Through its various projects and ongoing production momentum, Excellon Resources looks well positioned to capitalize on the precious metal’s renaissance. 

For more information, visit the company’s website at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Excellon Resources Inc. EXN | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

  • The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress
  • EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine
  • Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO

In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine.

“Our nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest among us,” said Dr. Alex Belser, Cybin’s chief clinical officer. “They’re experiencing high levels of anxiety, depression and burnout. Now it’s our turn to help them. We are sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress.”

The study, which Cybin will be co-sponsoring in a strategic collaboration with the University of Washington, will be hosted in Seattle, one of the cities hit hardest at the outset of the pandemic, and will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology. The randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals.

“There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future,” said Back, who will serve as primary investigator to the clinical trial.  

Designed to support the initiative, Cybin’s EMBARK model was developed by Belser and PhD candidate Bill Brennan. Cybin noted that the development of EMBARK has been guided by leading process evidence for the clinical efficacy of psychedelic-assisted psychotherapy and demonstrated theories of therapeutic action to support healing. “EMBARK was designed as a transdiagnostic psychotherapy model that can be adapted to address a range of clinical indications and populations,” the company stated.

“For more than a year now, frontline clinicians and healthcare professionals have made immeasurable sacrifices to protect public health in their communities,” said Cybin CEO Doug Drysdale. “We consider it an honor and our duty to now help support their own healing processes, post-COVID-19. We are also delighted and proud to launch EMBARK, a ground-breaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics. We look forward to working with and supporting Dr. Anthony Back on this important program.” 

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Cybin Inc. CLXPF | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that Covid-ID Lab sits between a rapid antigen test and a centralized automated high-throughput PCR and offers diagnostic quality, fast results and ease of administration at point of care.

To view the full press release, visit https://ibn.fm/Pu8h3

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in XPhyto Therapeutics Corp. XPHYF | Leave a comment

FingerMotion Inc. (FNGR) On Upward Trajectory as FYE Report Shows Record Growth, Dawning Big Data Revenues

  • China-focused communications technology company FingerMotion is riding a wave of optimism following FYE 2020 reporting that showed revenues have nearly reached $17 million and gross profits rose 71 percent
  • The company also saw the initial revenues from its new venture into big data, which it expects to become a primary driver of its business profile as it draws on mobile users’ information to power its predictive services
  • FingerMotion’s Sapientus platform for predictive services was a huge draw in establishing a landmark agreement with Pacific Life Re-insurance for Pacific Life’s insurtech solutions in China
  • Sapientus’ predictive database has the potential to become a powerful B2B resource for other industries as well, including health care, financial services and consumer e-commerce applications

Building on a trajectory of repeated reports of record revenue gains, evolving communications and insurance technology company FingerMotion (OTCQX: FNGR) is anticipating significant growth in mobile phone service sales during the coming year — potentially 20 to 30 percent in SMS short messaging services and as much as 1,000 percent in top-up airtime credit transfers. 

The company’s focus on rich communication services (“RCS”) and big-data insights in China’s huge marketplace for mobile products has positioned the U.S-based company for growth in the insurtech industry, particularly, where it anticipates acquiring service for more than a billion customers in the Southeast Asian nation. 

FingerMotion aims to build a communications ecosystem of active users of its innovative applications, drawing on partnerships with Alibaba’s (NYSE: BABA) TMALL sites, plus PinDuoDuo’s (NYSE: PDD) and JD.com’s (NASDAQ: JD) platforms. 

The company expects to thereby develop its access to users’ data to strengthen its Sapientus database IP, which has already led to a landmark agreement with Pacific Life Re-insurance that will help Pacific Life enhance its insurance solutions among Chinese clients and develop predictive consumer information that can serve as a substitute for a credit score system where a standard for such a system doesn’t already exist. 

“The Company is rapidly evolving and we saw the first indication of revenue (during the just-concluded fiscal year), albeit small ($33,077), from the Big Data Insights division,” CEO Martin Shen stated in reporting the company’s year-end financial position (https://ibn.fm/R39CC). “We are a technology company and believe our future lies in the Big Data Insights division. By the end of calendar 2021, we expect multiple contracts relating to our Insuretech products.”

FingerMotion foresees the possibility of its Sapientus database’s predictive services eventually serving the needs of other market sectors such as health care, financial services and consumer e-commerce applications as well. 

The FYE 2021 financial results reported an annual gross profit of $1.65 million, which was an increase of $0.68 million or 71 percent compared to FYE 2020. Annual revenues grew 82 percent to $16.68 million from all its sectors.

While general and administrative expenses also grew during the year, FingerMotion remains “steadfast in our belief that we will reach profitability in the near future,” Shen stated. 

The company’s shareholder equity, or its ability to cover its liabilities with its assets, ended the year in positive territory of $2.11 million, which Shen hailed as “a big step forward” for the company in meeting the qualifications for listing with senior exchanges. 

“For the past two years we have been driving revenue and profitability at the same time,” Shen stated. “We are constantly striving to optimize our resources.”

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in FingerMotion Inc. FNGR | Leave a comment

MissionIRNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Join Russell 2000 Index

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be added to the Russell 2000(R) Index effective Monday, June 28, 2021. The company will be added to the index at the conclusion of the 2021 Russell Indexes annual reconstitution. Investment managers and institutional investors often use the Russell U.S. Indexes, which are part of global index provider FTSE Russell, as a basis for index funds and as benchmarks for active investment strategies. According to the announcement, an estimated $10.6 trillion in assets are benchmarked against Russell U.S. Indexes. When a company is selected to join the all-cap Russell 3000(R) Index, the company is also automatically included in the large-cap Russell 1000(R) Index or small-cap Russell 2000)R Index, along with other appropriate growth- and value-style indexes. “Inclusion in the Russell 2000 Index, which is one of the most cited performance benchmarks for small-cap companies, is another important milestone for VistaGen and an achievement we expect will increase overall awareness and exposure of our company within the investment community,” said VistaGen CEO Shawn K. Singh. “Our late-stage anxiety and depression programs have exciting potential to change lives. We look forward to introducing our company to a wider investor audience as we continue to execute on noteworthy milestones during the second half of the year and beyond.”

To view the full press release, visit https://ibn.fm/K310x

About VistaGen Therapeutics Inc.

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in VistaGen Therapeutics Inc. VTGN | Leave a comment

Brain Scientific Inc. (BRSF) Poised to Contribute to Mental Health Research; Provides Technology to Map Brain Response to Psychedelic Treatment

  • BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
  • Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
  • BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way

Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://ibn.fm/eX4AD). 

Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://ibn.fm/6C81O). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when coupled with talking therapy (https://ibn.fm/BW9pa). This breakthrough could potentially have profound implications for a space that has seen few pharmacological advancements over recent decades regarding the treatment of mental disorders affecting millions of people around the world, including depression, anxiety, PTSD, addiction, and more. Still, experts caution that more research is needed. 

This is where the partnership between Brain Scientific and Ehave can potentially make a difference. The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI and linked data protocols to develop neural net algorithms. As an initial use case, the neural net algorithm would be used to upload an already trained neuronet into a specialized chip, a temporary E-Tattoo, developed by Brain Scientific.

Brain Scientific would also contribute to the collaboration by providing its proprietary data signal acquisition technology, NeuroCap, and NeuroEEG. These devices, designed to collect and read brain activity, would be linked to the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the required software, and hardware and will develop and validate products within three months of receiving any specifications from Ehave.

As part of the MoU, Ehave’s role would be to acquire real-time patients data from Brain Scientific’s NeuroCap and NeuroEEG and transfer it into a cloud. Both Ehave and Brain Scientific will jointly own the data from this collaboration. 

In addition, Ehave could seek to leverage its network of partner healthcare providers, including psychiatrists, psychologists, psychotherapists, and general practitioners, to use NeuroCap and NeuroEEG in clinical settings and collect the data about the electrophysiological changes in brain pre, mid and post-psychedelic drug administration. 

The collaboration could lead to building or partnering with functional labs where NeuroCap and NeuroEEG devices could be deployed to conduct market studies on consumer behavior and psychology and collect data on various brain-related physiological and mental disorders. These labs are likely to start in Australia and could be rolled out in other parts of the world where Ehave has its footprint. 

With E-Tattoo, an EEG device about the size of a stamp, Brain Scientific allows continuous measurement of patients’ brain activity in a non-intrusive way and with minimal distraction from everyday life. Brain Scientific believes that the future of EEG testing will be based on non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. Graphene, often called the wonder material of the 21st century, could potentially allow the development of smaller electrodes — even thinner than a human hair. The two companies are poised to leverage their unique expertise and work together to make a big step forward in neurological and psychiatric research by utilizing graph-based AI and linked data protocols to help develop biomarkers for psychiatric disorders.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Brain Scientific Inc. BRSF | Leave a comment

MissionIRNewsBreaks – Knightscope Inc.’s ASRs Providing Multiple Security Advantages

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”) focused on enhancing US security operations, offers a reasonable solution that could prove useful in various scenarios. “The company’s ASR offering is affordable, experienced and effective, and provides multiple security advantages,” reads a recent article. “The ASRs all feature the Knightscope Security Operations Center (“KSOC”) interface that provides real-time access to data around the clock, as well as 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection, among others.” Knightscope has released three models — K1, K3 and K5 — whose versatility and cost-efficiency position the company “as a leading provider of autonomous security solutions on the expanding global security robot market.”

To view the full article, visit https://ibn.fm/QAlF9

About Knightscope

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Knightscope, Inc. | Leave a comment

MissionIRNewsBreaks –Splash Beverage Group Inc. (NYSE American: SBEV) Closes on $15M Public Offering, Uplists to NYSE American

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, announced that it had closed on an underwritten public offering. The offering, which resulted in $15 million for the company before deductions, was comprised of 3,750,000 shares of common stock along with warrants to purchase another 3,750,000 shares of common stock. The price per share is $4; the warrants are also $4 each. The warrants are exercisable at $4.60 per share and will expire five years from issuance. According to the announcement, SBEV also granted the underwriters an option to purchase up to an additional 562,500 shares of common stock along with the same number of warrants. The common stock and warrants were issued separately. Splash Beverage also announced that its common stock and warrants began trading on the NYSE American, effective June 11, 2021; symbols for the stocks and warrants were SBEV and SBEV.WS respectively.

To view the full press release, visit https://ibn.fm/4ioKQ  

About Splash Beverage Group Inc.

Splash Beverage Groupspecializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the nonalcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique because it only develops and accelerates brands it perceives to have highly visible pre-existing brand awareness or pure category innovation. For more information about the company, please visit www.SplashBeverageGroup.com

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Splash Beverage Group Inc. SBEV | Leave a comment